Grace Therapeutics (GRCE) Net Cash Flow (2019 - 2026)
Grace Therapeutics (GRCE) posted Net Cash Flow of -$1.7 million for Q1 2026, down 193.65% sequentially from $1.8 million in Q4 2025, and down 115.3% YoY from $11.1 million in Q1 2025.
Grace Therapeutics (GRCE) Net Cash Flow (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Net Cash Flow for 8 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Net Cash Flow fell 115.3% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 491.28% YoY) and the FY2026 annual result came in at -$5.2 million, down 491.28% from the prior year.
- Net Cash Flow retreated to -$1.7 million in Q1 2026 per GRCE's latest filing, from $1.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $11.1 million in Q1 2025 and troughed at -$8.7 million in Q4 2022.
- A 5-year average of -$969882.4 and a median of -$3.1 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow surged 256.33% in 2023, then tumbled 179.14% in 2024.
- Over 5 years, Net Cash Flow stood at -$8.7 million in 2022, then rose by 3.18% to -$8.4 million in 2023, then jumped by 51.46% to -$4.1 million in 2024, then soared by 144.15% to $1.8 million in 2025, then tumbled by 193.65% to -$1.7 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$1.7 million, $1.8 million, and -$3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 225.59 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Jun 30, 2025 | -2.13 Mn |
| Jun 30, 2025 | -2.13 Mn |
| Mar 31, 2025 | 11.08 Mn |
| Mar 31, 2025 | 11.08 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Jun 30, 2024 | -3.61 Mn |
| Mar 31, 2024 | 4.46 Mn |
| Mar 31, 2024 | 4.46 Mn |